CO2017001596A2 - Biomarcadores de enfermedad poliquística renal y usos de los mismos - Google Patents

Biomarcadores de enfermedad poliquística renal y usos de los mismos

Info

Publication number
CO2017001596A2
CO2017001596A2 CONC2017/0001596A CO2017001596A CO2017001596A2 CO 2017001596 A2 CO2017001596 A2 CO 2017001596A2 CO 2017001596 A CO2017001596 A CO 2017001596A CO 2017001596 A2 CO2017001596 A2 CO 2017001596A2
Authority
CO
Colombia
Prior art keywords
patient
pkd
kinase
protein
phosphorylated
Prior art date
Application number
CONC2017/0001596A
Other languages
English (en)
Spanish (es)
Inventor
Oxana Beskrovnaya
Nikolai Bukanov
Sarah Moreno
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2017001596A2 publication Critical patent/CO2017001596A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CONC2017/0001596A 2014-08-04 2017-02-17 Biomarcadores de enfermedad poliquística renal y usos de los mismos CO2017001596A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
CO2017001596A2 true CO2017001596A2 (es) 2017-05-19

Family

ID=54035292

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0001596A CO2017001596A2 (es) 2014-08-04 2017-02-17 Biomarcadores de enfermedad poliquística renal y usos de los mismos

Country Status (12)

Country Link
US (1) US10871495B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6730252B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170033436A (cg-RX-API-DMAC7.html)
CN (1) CN106716136B (cg-RX-API-DMAC7.html)
AU (1) AU2015301278A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017002003A2 (cg-RX-API-DMAC7.html)
CO (1) CO2017001596A2 (cg-RX-API-DMAC7.html)
MX (1) MX2017001648A (cg-RX-API-DMAC7.html)
RU (1) RU2017106891A (cg-RX-API-DMAC7.html)
SG (1) SG11201700290SA (cg-RX-API-DMAC7.html)
WO (1) WO2016022500A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374499A1 (en) 1999-05-24 2000-11-30 Avi Biopharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
WO2010141862A2 (en) 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
US20140079769A1 (en) * 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
US10478446B2 (en) 2012-07-03 2019-11-19 Fondazione Centro San Raffaele Office Of Biotechnology Transfer Compounds for use in polycystic kidney disease
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
US10871495B2 (en) 2020-12-22
RU2017106891A (ru) 2018-09-06
RU2017106891A3 (cg-RX-API-DMAC7.html) 2019-03-14
JP2017525955A (ja) 2017-09-07
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
EP3177932B1 (en) 2021-07-14
KR20170033436A (ko) 2017-03-24
WO2016022500A3 (en) 2016-04-07
WO2016022500A2 (en) 2016-02-11
CN106716136B (zh) 2020-06-23
AU2015301278A1 (en) 2017-02-09
MX2017001648A (es) 2017-04-27
SG11201700290SA (en) 2017-02-27
EP3177932A2 (en) 2017-06-14
JP6730252B2 (ja) 2020-07-29
US20170227551A1 (en) 2017-08-10
JP2020170013A (ja) 2020-10-15
BR112017002003A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
IL292828A (en) Central memory t cells for adoptive t cell therapy
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
EP4084571C0 (en) PROHIBITION OF FAULT INDICATIONS FOR SECONDARY CELL GROUP FAILURE
IL262367A (en) Methods, systems and kits for sequestration pen-based assays
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
WO2012094580A3 (en) Compounds that modulate oxidative stress
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2018002634A (es) Impulsores de grapas de un cartucho de grapas quirurgicas con caracteristicas de soporte central.
CO2018012513A2 (es) Anticuerpos
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
PE20190229A1 (es) Anticuerpos anti-fcrn
MX374967B (es) Capas implantables que comprenden una region presionada.
BR112016028512A2 (pt) métodos de cultivo por perfusão e seu uso
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
SI3365432T1 (sl) Terapija z matičnimi celicami, na osnovi matičnih celic iz adipoze
MX2019006332A (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
MX2020003580A (es) Procedimiento para determinar la geometria de un defecto y para determinar un limite de carga.
BR112019001409A2 (pt) células renais bioativas para o tratamento de doença renal crônica
HK1244534A1 (zh) 重组疏螺旋体蛋白及其使用方法
MX2017001648A (es) Biomarcadores de enfermedad poliquistica renal y usos de los mismos.
BR112013028218A2 (pt) válvula para fabricação de solas de calçado ocas e método para uso das mesmas